Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison

Beatriz Gros; Nathan Constantine-Cooke; Jake Kennedy; Alexander T Elford; Claire O’Hare; Colin Noble; Gareth-Rhys Jones; Ian D Arnott; Charlie W Lees; Nikolas Plevris

doi:10.1093/ecco-jcc/jjae188

Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison

Beatriz Gros, Nathan Constantine-Cooke, Jake Kennedy, Alexander T Elford, Claire O’Hare, Colin Noble, Gareth-Rhys Jones, Ian D Arnott, Charlie W Lees^*, Nikolas Plevris

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Journal of Crohn's and Colitis
Early online date	11 Dec 2024
DOIs	https://doi.org/10.1093/ecco-jcc/jjae188
Publication status	E-pub ahead of print - 11 Dec 2024

Access to Document

10.1093/ecco-jcc/jjae188Licence: Creative Commons: Attribution (CC-BY)

Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted ComparisonAccepted author manuscript, 1.12 MBLicence: Creative Commons: Attribution (CC-BY)

https://academic.oup.com/ecco-jcc/advance-article/doi/10.1093/ecco-jcc/jjae188/7920833Licence: Creative Commons: Attribution (CC-BY)

Predicting disease flare and treatment response in inflammatory bowel disease
Lees, C.
UKRI (formerly RCUK)
1/11/19 → 31/10/24
Project: Research

Cite this

Gros, B., Constantine-Cooke, N., Kennedy, J., Elford, A. T., O’Hare, C., Noble, C., Jones, G.-R., Arnott, I. D., Lees, C. W., & Plevris, N. (2024). Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison. Journal of Crohn's and Colitis. Advance online publication. https://doi.org/10.1093/ecco-jcc/jjae188

@article{4ae48ef834484548b41e9a821100095f,

title = "Tofacitinib versus Vedolizumab Among Bio-na{\"i}ve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison",

author = "Beatriz Gros and Nathan Constantine-Cooke and Jake Kennedy and Elford, {Alexander T} and Claire O{\textquoteright}Hare and Colin Noble and Gareth-Rhys Jones and Arnott, {Ian D} and Lees, {Charlie W} and Nikolas Plevris",

year = "2024",

month = dec,

day = "11",

doi = "10.1093/ecco-jcc/jjae188",

language = "English",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Elsevier",

}

TY - JOUR

T1 - Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison

AU - Gros, Beatriz

AU - Constantine-Cooke, Nathan

AU - Kennedy, Jake

AU - Elford, Alexander T

AU - O’Hare, Claire

AU - Noble, Colin

AU - Jones, Gareth-Rhys

AU - Arnott, Ian D

AU - Lees, Charlie W

AU - Plevris, Nikolas

PY - 2024/12/11

Y1 - 2024/12/11

U2 - 10.1093/ecco-jcc/jjae188

DO - 10.1093/ecco-jcc/jjae188

M3 - Article

SN - 1873-9946

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

ER -

Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison

Access to Document

Projects

Predicting disease flare and treatment response in inflammatory bowel disease

Cite this